Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Information source: HRA Pharma
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Emergency Contraception
Intervention: ella (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: HRA Pharma Official(s) and/or principal investigator(s): Paul Fine, MD, Principal Investigator, Affiliation: Planned Parenthood Gulf Coast
Overall contact: Paul Fine, MD, Phone: +17138316553, Email: Paul.Fine@ppgulfcoast.org
Summary
The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies
exposed to ella, whether due to failure of the emergency contraception or inadvertent
exposure during pregnancy.
Clinical Details
Official title: Prospective Multicenter Observational Study to Assess Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Study design: Time Perspective: Prospective
Primary outcome: pregnancy outcome
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
- Pregnant women, exposed to ella during the menstrual cycle in which the pregnancy
started (treatment failure) or at any time during pregnancy (inadvertent exposure
during pregnancy)
- Adolescents and/or adults in the USA, depending on the respective State law
Locations and Contacts
Paul Fine, MD, Phone: +17138316553, Email: Paul.Fine@ppgulfcoast.org
Planned Parenthood Federation of America, Inc, New York,, New York 10001, United States; Recruiting
Additional Information
Starting date: January 2012
Last updated: September 18, 2014
|